甲状腺微小乳頭癌の取り扱いおよび遺伝子変異について

近年甲状腺癌に関する様々なガイドラインが改訂された。特に,国内のガイドラインで,転移や浸潤徴候のない微小乳頭癌患者に対して,非手術経過観察を希望される場合には,“経過観察を行うこと”が推奨された点は,他癌種の治療ストラテジーである早期発見,早期治療とは相反しており注目すべきである。この背景には,微小癌の増大頻度や遠隔転移の頻度は低いこと,増大後手術施行しても術後成績が変わらないことが前向き研究で示された為である。海外のガイドラインでは,次世代シーケンサーの普及に伴い,遺伝子検査が細胞診の鑑別困難時の診断補助として推奨されている。国内でも,髄様癌のRET遺伝子検査は,治療法決定に不可欠な検査であ...

Full description

Saved in:
Bibliographic Details
Published in頭頸部外科 Vol. 30; no. 1; pp. 5 - 9
Main Authors 伊藤, 公一, 杉野, 公則, 友田, 智哲
Format Journal Article
LanguageJapanese
Published 特定非営利活動法人 日本頭頸部外科学会 2020
Subjects
Online AccessGet full text
ISSN1349-581X
1884-474X
DOI10.5106/jjshns.30.5

Cover

Abstract 近年甲状腺癌に関する様々なガイドラインが改訂された。特に,国内のガイドラインで,転移や浸潤徴候のない微小乳頭癌患者に対して,非手術経過観察を希望される場合には,“経過観察を行うこと”が推奨された点は,他癌種の治療ストラテジーである早期発見,早期治療とは相反しており注目すべきである。この背景には,微小癌の増大頻度や遠隔転移の頻度は低いこと,増大後手術施行しても術後成績が変わらないことが前向き研究で示された為である。海外のガイドラインでは,次世代シーケンサーの普及に伴い,遺伝子検査が細胞診の鑑別困難時の診断補助として推奨されている。国内でも,髄様癌のRET遺伝子検査は,治療法決定に不可欠な検査である。
AbstractList 近年甲状腺癌に関する様々なガイドラインが改訂された。特に,国内のガイドラインで,転移や浸潤徴候のない微小乳頭癌患者に対して,非手術経過観察を希望される場合には,“経過観察を行うこと”が推奨された点は,他癌種の治療ストラテジーである早期発見,早期治療とは相反しており注目すべきである。この背景には,微小癌の増大頻度や遠隔転移の頻度は低いこと,増大後手術施行しても術後成績が変わらないことが前向き研究で示された為である。海外のガイドラインでは,次世代シーケンサーの普及に伴い,遺伝子検査が細胞診の鑑別困難時の診断補助として推奨されている。国内でも,髄様癌のRET遺伝子検査は,治療法決定に不可欠な検査である。
Author 伊藤, 公一
友田, 智哲
杉野, 公則
Author_xml – sequence: 1
  fullname: 伊藤, 公一
  organization: 伊藤病院
– sequence: 1
  fullname: 杉野, 公則
  organization: 伊藤病院
– sequence: 1
  fullname: 友田, 智哲
  organization: 伊藤病院
BookMark eNo9UE1LAlEUfYRBZq76HWP3-e58bYKQvkhoU-BueG_mlTOYxYybliMFKYEtKmgRtJA2oVhCkER_5jlN_osso8354Fwuh7NIMvXjuiRkmUJBp2CsBEFUrUcFNrVzJEstCzU0sZKZaoa2plu0skDyUeQLALARECFLdtLrl7T9-nU-Sj76yaAzfhtOHnrp3aWK-0nnVjXbn61nFZ-puK2aFyoeTuLR-P0-6V0l3VZ6M1Dxk4q7vwePS2T-gNcimf_jHNnfWN8rbWnl3c3t0lpZC4pogGYJY9qHCZsZoDPXQBdtD6FIkZuMInLhgck5SDA8lMwDwRlKtG0hEG3TYjmyOvsbRA1-KJ2T0D_i4anDw4bv1qQzG8Jh4NAf0P8Dt8pDJ-DsG64tdPI
ContentType Journal Article
Copyright 2020 特定非営利活動法人 日本頭頸部外科学会
Copyright_xml – notice: 2020 特定非営利活動法人 日本頭頸部外科学会
DOI 10.5106/jjshns.30.5
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
EISSN 1884-474X
EndPage 9
ExternalDocumentID article_jjshns_30_1_30_5_article_char_ja
GroupedDBID ABJNI
ACGFS
ALMA_UNASSIGNED_HOLDINGS
JSF
KQ8
RJT
ID FETCH-LOGICAL-j2460-8b63493b936053c64c49d40214a73144abd07aa0e06d4e3d0ba34e499bb449783
ISSN 1349-581X
IngestDate Wed Sep 03 06:28:17 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 1
Language Japanese
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-j2460-8b63493b936053c64c49d40214a73144abd07aa0e06d4e3d0ba34e499bb449783
OpenAccessLink https://www.jstage.jst.go.jp/article/jjshns/30/1/30_5/_article/-char/ja
PageCount 5
ParticipantIDs jstage_primary_article_jjshns_30_1_30_5_article_char_ja
PublicationCentury 2000
PublicationDate 20200000
PublicationDateYYYYMMDD 2020-01-01
PublicationDate_xml – year: 2020
  text: 20200000
PublicationDecade 2020
PublicationTitle 頭頸部外科
PublicationTitleAlternate 頭頸部外科
PublicationYear 2020
Publisher 特定非営利活動法人 日本頭頸部外科学会
Publisher_xml – name: 特定非営利活動法人 日本頭頸部外科学会
References 1)武部晃司,伊達 学,山本洋介,他:各領域癌における集団検診の限界 超音波検査を用いた甲状腺癌検診の実際とその問題点.KARKINOS,7:309-317,1994
8)Sugitani I: Active surveillance for very low-risk papillary thyroid carcinoma: experience and perspectives from Japan. Annals of Thyroid 3:1-15, 2018.
18)National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology. Thyroid Carcinoma Version 2:2019.
15)甲状腺腫瘍診療ガイドライン作成委員会:甲状腺腫瘍診療ガイドライン2018.日本内分泌,甲状腺外科学会雑誌,35(supplement 3):2018
2)Davis L, Welch HG: Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167, 2006.
4)Ito Y, Uruno T, Nakano K, et al: An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 13:381-387, 2003.
20)Wang JR, Zafereo ME, Dadu R, et al: Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAF V600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid 29:1036-1043, 2019.
7)Ito Y, Miyauchi A, Kihara M, et al: Patient age is siginificantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid 24:27-34, 2014.
11)Kim HI, Jang HW, Ahn HS, et al: High Serum TSH Level Is Associated With Progression of Papillary Thyroid Microcarcinoma During Active Surveillance. J Clin Endocrinol Metab 103:446-451, 2018.
13)Sugitani I, Ito Y, Miyauchi A, et al: Active Surveillance Versus Immediate Surgery: Questionnaire Survey on the Current Treatment Strategy for Adult Patients With Low-Risk Papillary Thyroid Microcarcinoma in Japan. Thyroid 29:1563-1571, 2019.
5)Oda H, Miyauchi A, Ito Y, et al: Incidences of Unfavorable Events in the Management of Low-Risk Papillary Microcarcinoma of the Thyroid by Active Surveillance Versus Immediate Surgery. Thyroid 26:150-1555, 2016.
9)Fukuoka O, Sigitani I, Ebina A, et al: Natural History of Asymptomatic Papillary Thyroid Microcarcinoma: Time-Dependent Changes in Calcification and Vascularity During Active Surveillance. World J Surg 40:529-537, 2016.
16)Tomoda C, Miyauchi A, Uruno T, et al: Cribriform-morular variant of papillary thyroid carcinoma: clue to early detection of familial adenomatous polyposis-associated colon cancer. World J Surg 28:886-889, 2004.
14)Haugen BR, Erik K, Alexander EK, et al: 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer Thyroid 26:1-133, 2016.
3)Ahn HS, Kim HJ, Welch HG: Korea’s thyroid-cancer “epidemic”-screening and overdiagnosis. N Engl J Med 371:1765-1767, 2014.
17)Meng Z, Matsuse M, Saenko V, et al: TERT promoter mutation in primary papillary thyroid carcinoma lesions predicts absent or lower 131i uptake in metastases. IUBMB Life 71:1030-1040, 2019.
6)Sugitani I, Toda K, Yamada K, et al: Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg 34:1222-1231, 2010.
12)Sakai T, Sugitani I, Ebina A, et al: Active Surveillance for T1bN0M0 Papillary Thyroid Carcinoma. Thyroid 29:59-63, 2019.
10)Sugitani I, Fujimoto Y, Yamada K: Association between serum thyrotropin concentration and growth of asymptomatic papillary thyroid microcarcinoma. World J Surg 38:673-678, 2014.
19)Subbiah V, Kreitman RJ, Wainberg ZA, et al: Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. J Clin Oncol 36:7-13, 2018.
References_xml – reference: 7)Ito Y, Miyauchi A, Kihara M, et al: Patient age is siginificantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid 24:27-34, 2014.
– reference: 9)Fukuoka O, Sigitani I, Ebina A, et al: Natural History of Asymptomatic Papillary Thyroid Microcarcinoma: Time-Dependent Changes in Calcification and Vascularity During Active Surveillance. World J Surg 40:529-537, 2016.
– reference: 19)Subbiah V, Kreitman RJ, Wainberg ZA, et al: Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. J Clin Oncol 36:7-13, 2018.
– reference: 14)Haugen BR, Erik K, Alexander EK, et al: 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer Thyroid 26:1-133, 2016.
– reference: 18)National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology. Thyroid Carcinoma Version 2:2019.
– reference: 1)武部晃司,伊達 学,山本洋介,他:各領域癌における集団検診の限界 超音波検査を用いた甲状腺癌検診の実際とその問題点.KARKINOS,7:309-317,1994.
– reference: 2)Davis L, Welch HG: Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167, 2006.
– reference: 5)Oda H, Miyauchi A, Ito Y, et al: Incidences of Unfavorable Events in the Management of Low-Risk Papillary Microcarcinoma of the Thyroid by Active Surveillance Versus Immediate Surgery. Thyroid 26:150-1555, 2016.
– reference: 12)Sakai T, Sugitani I, Ebina A, et al: Active Surveillance for T1bN0M0 Papillary Thyroid Carcinoma. Thyroid 29:59-63, 2019.
– reference: 20)Wang JR, Zafereo ME, Dadu R, et al: Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAF V600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid 29:1036-1043, 2019.
– reference: 3)Ahn HS, Kim HJ, Welch HG: Korea’s thyroid-cancer “epidemic”-screening and overdiagnosis. N Engl J Med 371:1765-1767, 2014.
– reference: 4)Ito Y, Uruno T, Nakano K, et al: An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 13:381-387, 2003.
– reference: 13)Sugitani I, Ito Y, Miyauchi A, et al: Active Surveillance Versus Immediate Surgery: Questionnaire Survey on the Current Treatment Strategy for Adult Patients With Low-Risk Papillary Thyroid Microcarcinoma in Japan. Thyroid 29:1563-1571, 2019.
– reference: 15)甲状腺腫瘍診療ガイドライン作成委員会:甲状腺腫瘍診療ガイドライン2018.日本内分泌,甲状腺外科学会雑誌,35(supplement 3):2018.
– reference: 17)Meng Z, Matsuse M, Saenko V, et al: TERT promoter mutation in primary papillary thyroid carcinoma lesions predicts absent or lower 131i uptake in metastases. IUBMB Life 71:1030-1040, 2019.
– reference: 10)Sugitani I, Fujimoto Y, Yamada K: Association between serum thyrotropin concentration and growth of asymptomatic papillary thyroid microcarcinoma. World J Surg 38:673-678, 2014.
– reference: 16)Tomoda C, Miyauchi A, Uruno T, et al: Cribriform-morular variant of papillary thyroid carcinoma: clue to early detection of familial adenomatous polyposis-associated colon cancer. World J Surg 28:886-889, 2004.
– reference: 6)Sugitani I, Toda K, Yamada K, et al: Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg 34:1222-1231, 2010.
– reference: 11)Kim HI, Jang HW, Ahn HS, et al: High Serum TSH Level Is Associated With Progression of Papillary Thyroid Microcarcinoma During Active Surveillance. J Clin Endocrinol Metab 103:446-451, 2018.
– reference: 8)Sugitani I: Active surveillance for very low-risk papillary thyroid carcinoma: experience and perspectives from Japan. Annals of Thyroid 3:1-15, 2018.
SSID ssib000940440
ssj0000389136
Score 2.212591
Snippet 近年甲状腺癌に関する様々なガイドラインが改訂された。特に,国内のガイドラインで,転移や浸潤徴候のない微小乳頭癌患者に対して,非手術経過観察を希望される場合には,“...
SourceID jstage
SourceType Publisher
StartPage 5
SubjectTerms 微小乳頭癌
次世代シーケンサー
遺伝子検査
非手術経過観察
Title 甲状腺微小乳頭癌の取り扱いおよび遺伝子変異について
URI https://www.jstage.jst.go.jp/article/jjshns/30/1/30_5/_article/-char/ja
Volume 30
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX 頭頸部外科, 2020, Vol.30(1), pp.5-9
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1884-474X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000389136
  issn: 1349-581X
  databaseCode: KQ8
  dateStart: 19910101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1PaxQxFB9qvXgRRcX_9GCOo-kkk0mOme2UoigILfS2bGamyB6q2O3F2xQFuwj1oIIHwUPxIi3VgmARv8x0XXvwO_heMrM7lB7aXobHy8t7L_lt9r1kkonn3aGpCKKlUPk5E0s-zyn3DYQVPzBpwHORSof0w0diboHfXwwXJ878a-xaWu2Zu-mLI8-VnAZV4AGueEr2BMiOlAIDaMAXnoAwPI-FMUkiojiJAySkJrEgiSQyJLEmCTwTohNLUCJnSQKSisSMJIpoSvSMra6IbJGEQUZZCYOkEpYToM5EEAm1pisZyWtC1zKy4jjNSGhrq0XUDCoEQ4pagqMqNGpdqozGNcEPm9CimTo33LZELK05RrSslKPbEdGgf_Q7qhxBZyVREUrBb8o2E6q0bDH0GB3LC_Qa3QTd0KnJIfkQy8bBu-owGddQUCcvsGMdCooBQM3FlYCOBoLFTSEs2IKEKI12wQFloYAGIaQh9rFWqDUGE7HlxNiLyGGW4Ggt1s40tNOWqZb1-QT9VuGlRY2gbkQtxpUfSnv3EAR1x5OS-zxy21_rUFe9AmsOaRe3wkYCpI6KrPDXjYs83e7KExgyDBjjBGK0rbMaCG0n1WYwv8RH2K4L8CRhuwvTmbNBBIkh7qF43JgNKI4XoI-WSKl9h27PB9YNdCds0Zl7DVcge-zCXKreh2lTw_kL3vlqTjelnfmL3kS3c8l7MHz3fdj_8ffV3uD39mBnY__n7sHnreHHN2WxPdj4UK71_6x_K4uXZdEv116Xxe5Bsbf_69Ng6-1gc334fqcsvpbFphX4ctlbmE3mW3N-dXOJ3w24oL40AjxmRjEBQS4VPOUq4_h5wk7EpjnvmIxGnQ7Nqch4zjJqOoznXCljOF75yK54k8tPl_Or3hSNIsOyHCY2GeOpySACwxyIBfiZpSCPzDUvcm1vP3Ofp2kfF4Xrp655wzuHg8WtRN70JnvPV_NbkJv3zG2L6H9virj4
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E7%94%B2%E7%8A%B6%E8%85%BA%E5%BE%AE%E5%B0%8F%E4%B9%B3%E9%A0%AD%E7%99%8C%E3%81%AE%E5%8F%96%E3%82%8A%E6%89%B1%E3%81%84%E3%81%8A%E3%82%88%E3%81%B3%E9%81%BA%E4%BC%9D%E5%AD%90%E5%A4%89%E7%95%B0%E3%81%AB%E3%81%A4%E3%81%84%E3%81%A6&rft.jtitle=%E9%A0%AD%E9%A0%B8%E9%83%A8%E5%A4%96%E7%A7%91&rft.au=%E4%BC%8A%E8%97%A4%2C+%E5%85%AC%E4%B8%80&rft.au=%E6%9D%89%E9%87%8E%2C+%E5%85%AC%E5%89%87&rft.au=%E5%8F%8B%E7%94%B0%2C+%E6%99%BA%E5%93%B2&rft.date=2020&rft.pub=%E7%89%B9%E5%AE%9A%E9%9D%9E%E5%96%B6%E5%88%A9%E6%B4%BB%E5%8B%95%E6%B3%95%E4%BA%BA+%E6%97%A5%E6%9C%AC%E9%A0%AD%E9%A0%B8%E9%83%A8%E5%A4%96%E7%A7%91%E5%AD%A6%E4%BC%9A&rft.issn=1349-581X&rft.eissn=1884-474X&rft.volume=30&rft.issue=1&rft.spage=5&rft.epage=9&rft_id=info:doi/10.5106%2Fjjshns.30.5&rft.externalDocID=article_jjshns_30_1_30_5_article_char_ja
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1349-581X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1349-581X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1349-581X&client=summon